Saturn V Capital Management LP
CIK: 1964437
Holdings (23)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 14, 2026
- AMLX
AMYLYX PHARMACEUTICALS INC
$83.05M
4.62M sh11.91%+6.3% - ALMS
ALUMIS INC
$82.04M
2.92M sh11.76%-8.9% - ABVX
ABIVAX SA
$69.14M
518,865 sh9.91%-4.4% - PCVX
VAXCYTE INC
$49.58M
852,914 sh7.11%+3.4% - IMMX
IMMIX BIOPHARMA INC
$48.03M
4.66M sh6.89%+26.1% - PHVS
PHARVARIS N V
$45.44M
1.31M sh6.52%+9.4% - JAZZ
JAZZ PHARMACEUTICALS PLC
$38.78M
160,938 sh5.56%-1.2% - CELC
CELCUITY INC
$38.74M
370,318 sh5.55%+31.4% - IRON
DISC MEDICINE INC
$38.38M
524,730 sh5.50%+16.6% - CADL
CANDEL THERAPEUTICS INC
$34.03M
3.30M sh4.88%+14.1% - XFOR
X4 PHARMACEUTICALS INC
$32.57M
6.97M sh4.67%+8.0% - MNPR
MONOPAR THERAPEUTICS INC
$28.89M
311,976 sh4.14%-9.7% - DYN
DYNE THERAPEUTICS INC
$23.49M
1.06M sh3.37%+9.4% - TRVI
TREVI THERAPEUTICS INC
$19.62M
1.05M sh2.81%New - ZURA
ZURA BIO LTD
$12.4M
2.10M sh1.78%+183.9% - SGMT
SAGIMET BIOSCIENCES INC
$11.44M
1.48M sh1.64%New - OCS
OCULIS HOLDING AG
$9.5M
684,880 sh1.36%+32.5% - IKT
INHIBIKASE THERAPEUTICS INC
$7.85M
3.87M sh1.13%+0.1% - VIR
VIR BIOTECHNOLOGY INC
$7.85M
770,643 sh1.13%New - IVVD
INVIVYD INC
$7.32M
8.39M sh1.05%-23.4% - ANRO
ALTO NEUROSCIENCE INC
$4.82M
182,829 sh0.69%+105.4% - MSLE
SATELLOS BIOSCIENCE INC
$2.72M
350,000 sh0.39%+0.0% - OVID
OVID THERAPEUTICS INC
$1.78M
663,060 sh0.26%-84.1%
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 AMLX AMYLYX PHARMACEUTICALS INC | 4.62M | $83.05M | +6.3% | 11.91% | Q2 2026 |
 ALMS ALUMIS INC | 2.92M | $82.04M | -8.9% | 11.76% | Q2 2026 |
 ABVX ABIVAX SA | 518,865 | $69.14M | -4.4% | 9.91% | Q2 2026 |
 PCVX VAXCYTE INC | 852,914 | $49.58M | +3.4% | 7.11% | Q2 2026 |
 IMMX IMMIX BIOPHARMA INC | 4.66M | $48.03M | +26.1% | 6.89% | Q2 2026 |
 PHVS PHARVARIS N V | 1.31M | $45.44M | +9.4% | 6.52% | Q2 2026 |
 JAZZ JAZZ PHARMACEUTICALS PLC | 160,938 | $38.78M | -1.2% | 5.56% | Q2 2026 |
 CELC CELCUITY INC | 370,318 | $38.74M | +31.4% | 5.55% | Q2 2026 |
 IRON DISC MEDICINE INC | 524,730 | $38.38M | +16.6% | 5.50% | Q2 2026 |
 CADL CANDEL THERAPEUTICS INC | 3.30M | $34.03M | +14.1% | 4.88% | Q2 2026 |
 XFOR X4 PHARMACEUTICALS INC | 6.97M | $32.57M | +8.0% | 4.67% | Q2 2026 |
 MNPR MONOPAR THERAPEUTICS INC | 311,976 | $28.89M | -9.7% | 4.14% | Q2 2026 |
 DYN DYNE THERAPEUTICS INC | 1.06M | $23.49M | +9.4% | 3.37% | Q2 2026 |
 TRVI TREVI THERAPEUTICS INC | 1.05M | $19.62M | New | 2.81% | Q2 2026 |
 ZURA ZURA BIO LTD | 2.10M | $12.4M | +183.9% | 1.78% | Q2 2026 |
 SGMT SAGIMET BIOSCIENCES INC | 1.48M | $11.44M | New | 1.64% | Q2 2026 |
 OCS OCULIS HOLDING AG | 684,880 | $9.5M | +32.5% | 1.36% | Q2 2026 |
 IKT INHIBIKASE THERAPEUTICS INC | 3.87M | $7.85M | +0.1% | 1.13% | Q2 2026 |
 VIR VIR BIOTECHNOLOGY INC | 770,643 | $7.85M | New | 1.13% | Q2 2026 |
 IVVD INVIVYD INC | 8.39M | $7.32M | -23.4% | 1.05% | Q2 2026 |
 ANRO ALTO NEUROSCIENCE INC | 182,829 | $4.82M | +105.4% | 0.69% | Q2 2026 |
 MSLE SATELLOS BIOSCIENCE INC | 350,000 | $2.72M | +0.0% | 0.39% | Q2 2026 |
 OVID OVID THERAPEUTICS INC | 663,060 | $1.78M | -84.1% | 0.26% | Q2 2026 |
1-23 of 23 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Saturn V Capital Management LP
Saturn V Capital Management LP is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1964437). Signal8 holds 20 13F filings from it. Its SEC filings list Delaware as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 14, 2026. That report lists 23 securities, not counting options, up from 21 in Q1 2026.
Its five largest reported positions, in order, are AMYLYX PHARMACEUTICALS INC (AMLX), ALUMIS INC (ALMS), ABIVAX SA (ABVX), VAXCYTE INC (PCVX) and IMMIX BIOPHARMA INC (IMMX). The next five are PHARVARIS N V (PHVS), JAZZ PHARMACEUTICALS PLC (JAZZ), CELCUITY INC (CELC), DISC MEDICINE INC (IRON) and CANDEL THERAPEUTICS INC (CADL).
Recent 13F filings by Saturn V Capital Management LP
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 23 securities.
- Q1 2026: 13F-HR filed May 15, 2026, listing 21 securities.
- Q4 2025: 13F-HR filed Feb 17, 2026, listing 20 securities.
- Q3 2025: 13F-HR filed Nov 14, 2025, listing 17 securities.
- Q2 2025: 13F-HR filed Aug 13, 2025, listing 24 securities.
- Q1 2025: 13F-HR filed May 15, 2025, listing 21 securities.